Compare Quest Diagnostics Inc (DGX) vs Opendoor Technologies Inc (OPEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Opendoor Technologies Inc — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Opendoor Technologies Inc trades at $4.62 (market cap $4.39B). The key difference: Quest Diagnostics Inc is far larger — about 5.2× Opendoor Technologies Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Opendoor Technologies Inc pays none. Which is the better fit depends on your goals.
| DGX | OPEN | |
|---|---|---|
Market Cap | $22.80B | $4.39B |
Sector | Health | Real Estate |
52-Week High | $216.02 | $10.52 |
52-Week Low | $166.42 | $1.04 |
Enterprise Value | $28.82B | $4.73B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Opendoor (OPEN) trades at $4.485, down 5.86% today, reflecting ongoing volatility amid a challenging housing market. The stock shows a bearish technical trend with support near $4 and resistance at $5. Fundamentally, the company reported a net loss of $1.30 billion on $4.37 billion revenue in 2025, with a negative net margin of 35.25%. Recent news highlights CEO leadership and a shift toward AI, including the closure of India operations affecting 250 employees (Reuters, 2026-06-11).
The outlook remains cautious due to persistent losses and high debt, though the low P/S ratio of 0.94 offers some valuation appeal. Risks include execution of the new business model, interest rate sensitivity, and competitive pressure. Analyst sentiment is mixed with 65.39% hold ratings, indicating wait-and-see approach until sustained profitability emerges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Opendoor Technologies Inc
Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →
